ScreenerHero

GANX Gain Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · gaintherapeutics.com
1.670USD0.00%Mkt Cap: 72.88M $P/E: —

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap72.88M USD
Enterprise Value60.41M USD
Revenue (TTM)—
Gross Profit-9.99M USD
Net Income (TTM)-20.16M USD
Revenue/Share—
Last Price1.670 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees20
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.43
PEG—
EV/EBITDA-3.14
EV/Revenue—
P/S—
P/B6.40
EPS (TTM)-0.50
EPS (Forward)-0.69
52W Range
1.5305% of range4.340
52W High4.340 USD
52W Low1.530 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-108.60%
ROA-88.35%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-18.47M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-15.28%
Net Debt-12.47M USD
Net Debt/EBITDA0.65
Balance Sheet
Debt/Equity0.04
Current Ratio4.36
Quick Ratio4.11
Book Value/Sh0.26 USD
Cash/Share0.30 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)7.200 USD
Upside (mean)+331.1%
Target Range5.000 USD – 8.000 USD
5.000+331.1% to mean8.000
# Analysts5
Ownership
Shares Out.43.64M
Float42.64M
Insiders2.23%
Institutions19.87%
Short Interest
Short Ratio8.3d
Short % Float6.77%
Short % Out.6.62%
Shares Short2.89M
Short (prev mo.)2.95M
Technical
SMA 501.831 (-8.8%)
SMA 2002.001 (-16.5%)
Beta0.19
S&P 52W Chg16.45%
Avg Vol (30d)422.75K
Avg Vol (10d)562.21K
Technical Indicators
RSI (14)40.7
MACD-0.0406
MACD Signal-0.0297
MACD Hist.-0.0109
BB Upper1.901 USD
BB Middle1.756 USD
BB Lower1.610 USD
BB Width16.52%
ATR (14)0.1004 USD
Vol Ratio (20d)0.78x